Home » Case Studies » Commercial Strategic Planning » Commercial Portfolio Strategy

Commercial Portfolio Strategy

CBPartners developed a commercial portfolio strategy for three clinical stage assets being investigated across five different liver disease indications.


To craft a development plan for the client’s liver disease portfolio that will maximize the collective opportunity across nonalcoholic steatohepatitis (NASH), Primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC), alcoholic hepatitis (AH), and hepatocellular carcinoma (HCC).



Conduct in-depth discussions and working sessions with the CLIENT’s clinical and commercial teams to align on viable portfolio scenarios and quantitatively and qualitatively evaluate the selected scenarios to suggest and pressure-test a launch strategy.


  • Interactive excel tool and uptake model with dynamic inputs tailored to each of the tested scenarios
  • Final deliverable incorporating model findings and internal CBP expertise to evaluate the trade-offs of each scenario
  • Comprehensive launch sequencing playbook

Illustrative Outputs


CBP provided a detailed analysis and forecasting for an extensive portfolio with numerous scenarios to maximize the portfolio opportunity.